基于网络药理学和分子对接分析续断-桑寄生改善多囊卵巢综合征的作用机制

doi:10.3976/j.issn.1002-4026.2022.03.002

Abstract

Abstract:

The study's aim was to explore the main active ingredients, targets, and pathways of the combined medicine, Dipsaci Radix-Taxilli Herba, involved in the improvement of polycystic ovary syndrome via network pharmacology. The main active ingredients and potential targets of Dipsaci Radix-Taxilli Herba were obtained through the traditional Chinese medicine(TCM) systems pharmacology database and analysis platform, and the TCM-ingredient-target network was constructed using the Cytoscape software. The disease targets of polycystic ovary syndrome were obtained through Disgenet and OMIM databases, and they were compared to obtain common drugs and disease targets with the help of online venn tools. Protein-protein interaction network was constructed using the STRING database, and Kyoto encyclopedia of genes and genomes(KEGG) pathway and gene ontology(GO) enrichment analyses were performed for the intersecting targets using Metascape database. Furthermore, the ingredient-target-pathway network was constructed via the Cytoscape software, and the reliability of inter-target binding was verified using the molecular docking technique. Among the 174 screened targets of the combined medicine, 80 common targets intersected with polycystic ovary syndrome, which mainly included cancer, hepatitis C signaling, AGE-RAGE signaling in diabetic complications, and other signaling pathways. The medicine, Dipsaci Radix-Taxilli Herba, forms multitarget and multichannel regulatory network through quercetin, β-sitosterol, and other active substances; improves hormone metabolism; reduces inflammatory cytokine levels; and achieves the goal of systemic improvement in polycystic ovary syndrome.

Key words: :polycystic ovary syndrome, Dipsaci Radix, Taxilli Herba, network pharmacology, molecular docking

CLC Number:

R285

HAN Cong,XIA Ming-hong,HU Yuan-long,ZHANG Jian-wei. Analysis of the mechanism of Dipsaci Radix-Taxilli Herba underlying the improvement of polycystic ovary syndrome via network pharmacology and molecular docking[J].Shandong Science, 2022, 35(3): 7-16.

Figures/Tables 10

Table 1

Fig.1

Fig.2

Fig.3

Fig.4

Table 2

Table 3

Table 4

Fig.5

Fig.6

References 37

[1]	赵晓苗, 杨冬梓. 多囊卵巢综合征的临床症状及远期影响[J]. 实用妇产科杂志, 2018, 34(8):566-570.
[2]	FRANKS S, GHARANI N, MCCARTHY M. Candidate genesin polycystic ovary syndrome[J]. Human Reproduction Update, 2001, 7(4): 405-410. DOI: 10.1093/humupd/7.4.405. doi: 10.1093/humupd/7.4.405
[3]	宋颖, 李蓉. 多囊卵巢综合征中国诊疗指南解读[J]. 实用妇产科杂志, 2018, 34(10):737-741.
[4]	黄三秀, 刘志红. 补肾化痰方对多囊卵巢综合征患者高雄激素血症的影响[J]. 河南中医, 2016, 36(6): 1073-1075. DOI: 10.16367/j.issn.1003-5028.2016.06.0447. doi: 10.16367/j.issn.1003-5028.2016.06.0447
[5]	曾蕾, 林欣仪, 曾芳冬, 等. 罗颂平治疗肾虚痰湿型多囊卵巢综合征中药周期序贯疗法规律探讨[J]. 时珍国医国药, 2020, 31(5):1247-1250.
[6]	柳井杜莎. 肖承悰教授治疗肾虚痰瘀型PCOS的临床疗效观察及用药规律分析[D]. 北京: 北京中医药大学, 2018.
[7]	HOPKINS A L. Network pharmacology: The next paradigm in drugdiscovery[J]. Nature Chemical Biology, 2008, 4(11): 682-690. DOI: 10.1038/nchembio.118. doi: 10.1038/nchembio.118
[8]	袁仁智, 唐鹏, 肖卫琼, 等. 当归-菟丝子干预肾虚血瘀型多囊卵巢综合征网络药理学作用机制[J]. 新中医, 2020, 52(3): 83-88. DOI: 10.13457/j.cnki.jncm.2020.03.025. doi: 10.13457/j.cnki.jncm.2020.03.025
[9]	肖卫琼, 袁仁智, 康开彪. 半夏-苍术-香附组药干预痰湿型多囊卵巢综合征的生物机制[J]. 中医药导报, 2020, 26(13): 144-150. DOI: 10.13862/j.cnki.cn43-1446/r.2020.13.033. doi: 10.13862/j.cnki.cn43-1446/r.2020.13.033
[10]	高雪枝. 桑寄生续断妇科临床运用举偶[J]. 陕西中医函授, 1985, 5(3): 44-45. DOI: 10.13424/j.cnki.mtcm.1985.03.011. doi: 10.13424/j.cnki.mtcm.1985.03.011
[11]	万全. 万氏妇人科[M]. 武汉: 湖北人民出版社, 1983.
[12]	SARRAY S, ALMAWI W Y. Levels of CD40L and other inflammatory biomarkers in obese and non-obese women with polycystic ovary syndrome[J]. American Journal of Reproductive Immunology, 2016, 76(4): 285-291. DOI: 10.1111/aji.12549. doi: 10.1111/aji.12549
[13]	任小胖, 刘梅梅, 陈亮, 等. 多囊卵巢综合征患者血清核因子-κβ和转化生长因子β1的表达及其与胰岛素抵抗的相关性研究[J]. 生殖与避孕, 2013, 24(8): 529-533. DOI: 10.7669/j.issn.0253-357X.2013.08.0529. doi: 10.7669/j.issn.0253-357X.2013.08.0529
[14]	黄丽红, 俞超芹, 张丹英. 多囊卵巢综合征高雄激素血症及慢性炎症的相关性研究进展[J]. 生殖与避孕, 2014, 34(11):936-939.DOI: 10.7669/j.issn.0253-357X.2014.11.0936. doi: 10.7669/j.issn.0253-357X.2014.11.0936
[15]	POURTEYMOUR FARD TABRIZI F, HAJIZADEH-SHARAFABAD F, VAEZI M, et al. Quercetin and polycystic ovary syndrome, current evidence and future directions: A systematic review[J]. Journal of Ovarian Research, 2020, 13(1): 11. DOI: 10.1186/s13048-020-0616-z. doi: 10.1186/s13048-020-0616-z
[16]	KHORSHIDI M, MOINI A, ALIPOOR E, et al. The effects of quercetin supplementation on metabolic and hormonal parameters as well as plasma concentration and gene expression of resistin in overweight or obese women with polycystic ovary syndrome[J]. Phytotherapy Research, 2018, 32(11): 2282-2289. DOI: 10.1002/ptr.6166. doi: 10.1002/ptr.6166
[17]	REZVAN N, MOINI A, JANANI L, et al. Effects of quercetin on adiponectin-mediated insulin sensitivity in polycystic ovary syndrome: A randomized placebo-controlled double-blind clinical trial[J]. Hormone and Metabolic Research, 2017, 49(2): 115-121. DOI: 10.1055/s-0042-118705. doi: 10.1055/s-0042-118705
[18]	REZVAN N, MOINI A, GORGANI-FIRUZJAEE S, et al. Oral quercetin supplementation enhances adiponectin receptor transcript expression in polycystic ovary syndrome patients: A randomizedplacebo-controlled double-blind clinical trial[J]. Cell Journal, 2018, 19(4): 627-633.DOI: 10.22074/cellj.2018.4577. doi: 10.22074/cellj.2018.4577
[19]	JAYAPRAKASHA G K, MANDADI K K, POULOSE S M, et al. Inhibition of colon cancer cell growth and antioxidant activity of bioactive compounds from Poncirus trifoliata (L.) Raf[J]. Bioorganic & Medicinal Chemistry, 2007, 15(14): 4923-4932. DOI: 10.1016/j.bmc.2007.04.044. doi: 10.1016/j.bmc.2007.04.044
[20]	PANIAGUA-PÉREZ R, MADRIGAL-BUJAIDAR E, REYES-CADENA S, et al. Cell protection induced by beta-sitosterol: Inhibition of genotoxic damage, stimulation of lymphocyte production, and determination of its antioxidant capacity[J]. Archives of Toxicology, 2008, 82(9): 615-622. DOI: 10.1007/s00204-007-0277-3. doi: 10.1007/s00204-007-0277-3
[21]	AHERNE S A, O'BRIEN N M. Modulation of cytokine production by plant sterols in stimulated human Jurkat T cells[J]. Molecular Nutrition & Food Research, 2008, 52(6): 664-673.DOI: 10.1002/mnfr.200700385. doi: 10.1002/mnfr.200700385
[22]	周路, 徐宝成, 尤思聪, 等. 植物甾醇生理功能及安全性评估研究新进展[J]. 中国粮油学报, 2020, 35(6): 196-202.
[23]	TASYRIQ M, NAJMULDEEN I A, IN L L A, et al. 7α-hydroxy-β-sitosterol from Chisocheton tomentosus Induces apoptosis via dysregulation of cellular bax/bcl-2 ratio and cell cycle arrest by downregulating ERK1/2 activation[J]. Evidence-Based Complementary and Alternative Medicine, 2012, 2012: 1-12. DOI: 10.1155/2012/765316. doi: 10.1155/2012/765316
[24]	CHOI J N, CHOI Y H, LEE J M, et al. Anti-inflammatory effects of β-sitosterol-β-D-glucoside from Trachelospermumjasminoides (Apocynaceae) in lipopolysaccharide-stimulated RAW 264.7 murine macrophages[J]. Natural Product Research, 2012, 26(24): 2340-2343.DOI: 10.1080/14786419.2012.654608. doi: 10.1080/14786419.2012.654608
[25]	代琪, 叶臻, 叶俏波, 等. 续断来源考证、化学成分及药理作用综述[J]. 中国药物评价, 2020, 37(6): 432-436.
[26]	陈大霞. 川续断属药用植物亲缘关系研究与川续断种质资源的综合评价[D]. 重庆: 重庆大学, 2014.
[27]	WU C Y, JIANG F, WEI K, et al. Exercise activates the PI3K-AKT signal pathway by decreasing the expression of 5α-reductase type 1 in PCOS rats[J]. Scientific Reports, 2018, 8: 7982. DOI: 10.1038/s41598-018-26210-0. doi: 10.1038/s41598-018-26210-0
[28]	GARABADU D, KRISHNAMURTHY S. Metformin attenuates hepatic insulin resistance in type-2 diabetic rats through PI3K/Akt/GLUT-4 signalling independent to bicuculline-sensitive GABAA receptor stimulation[J]. Pharmaceutical Biology, 2017, 55(1): 722-728. DOI: 10.1080/13880209.2016.1268635. DOI: 10.1002/mnfr.201500509. doi: 10.1002/mnfr.201500509
[29]	LIU K, MEI F, WANG Y P, et al. Quercetin oppositely regulates insulin-mediated glucose disposal in skeletal muscleunder normal and inflammatory conditions: The dual roles of AMPK activation[J]. Molecular Nutrition & Food Research, 2016, 60(3): 551-565. DOI: 10.1002/mnfr.201500509. doi: 10.1002/mnfr.201500509
[30]	LI N, WANG X Y, WANG X J, et al. Upregulation of FoxO 1 signaling mediates the proinflammatory cytokine upregulation in the macrophage from polycystic ovary syndrome patients[J]. Clinical Laboratory, 2017, 63(2): 301-311. DOI: 10.7754/Clin.Lab.2016.160514. doi: 10.7754/Clin.Lab.2016.160514
[31]	WANG Z Z, ZHAI D X, ZHANG D Y, et al. Quercetin decreases insulin resistance in a polycystic ovary syndrome rat model by improving inflammatory microenvironment[J]. Reproductive Sciences (Thousand Oaks, Calif), 2017, 24(5): 682-690. DOI: 10.1177/1933719116667218. doi: 10.1177/1933719116667218
[32]	FASSHAUER M, KLEIN J, LOSSNER U, et al. Interleukin (IL)-6 mRNA expression is stimulated by insulin, isoproterenol,tumour necrosis factor alpha, growth hormone, and IL-6 in 3T3-L1 adipocytes[J]. Hormone and Metabolic Research, 2003, 35(3): 147-152. DOI: 10.1055/s-2003-39075. doi: 10.1055/s-2003-39075
[33]	胡静, 杨菁, 徐望明, 等. TGF-β1、TNF-α、IL-6与多囊卵巢综合征发病关系的探讨[J]. 实用医学杂志, 2004, 20(11): 1237-1239.
[34]	洪岭, 伍园园, 唐传玲, 等. IL-6促进胰岛细胞胰岛素分泌在PCOS发病机制中的作用[J]. 同济大学学报(医学版), 2017, 38(1): 40-43.DOI: 10.16118/j.1008-0392.2017.01.008. doi: 10.16118/j.1008-0392.2017.01.008
[35]	陈央娣, 傅萍, 邢佳. 复方星夏汤对痰湿型多囊卵巢综合征模型小鼠肿瘤坏死因子-α、白细胞介素-6的影响[J]. 中华中医药学刊, 2017, 35(7): 1813-1816. DOI: 10.13193/j.issn.1673-7717.2017.07.048. doi: 10.13193/j.issn.1673-7717.2017.07.048
[36]	ORÓSTICA L, ASTORGA I, PLAZA-PARROCHIA F, et al. Proinflammatory environment and role of TNF-α in endometrial function of obese women having polycystic ovarian syndrome[J]. International Journal of Obesity, 2016, 40(11): 1715-1722. DOI: 10.1038/ijo.2016.154. doi: 10.1038/ijo.2016.154
[37]	王凡. HIF-1信号通路在多囊卵巢综合征中的作用及其调控机制[D]. 福州: 福建师范大学, 2017.

中药	编码	活性化合物	OB%	DL	编号
续断	MOL003152	Gentisin	64.06	0.21	XD1
续断,桑寄生	MOL000358	beta-sitosterol	36.91	0.75	A
续断	MOL000651	Sweroside aglycone	68.68	0.08	XD2
续断	MOL009312	(E,E)-3,5-Di-O-caffeoylquinic acid	48.14	0.68	XD3
续断	MOL009314	Cantleyine	70.62	0.08	—
续断	MOL009317	Cauloside A	43.32	0.81	—
续断	MOL008188	Japonine	44.11	0.25	—
续断	MOL009322	Sylvestroside III	48.02	0.53	XD4
桑寄生	MOL000119	ZINC02040970	40.43	0.43	SJS1
桑寄生	MOL000125	(-)-alpha-Pinene	46.25	0.06	SJS2
桑寄生	MOL000130	CAM	67.17	0.05	SJS3
桑寄生	MOL000193	(Z)-caryophyllene	30.29	0.05	SJS4
桑寄生	MOL000098	quercetin	46.43	0.75	SJS5

序号	生物学功能	基因数	P值
1	蛋白结构域特异性结合	16	5.25×10^-9
2	脂质结合	15	3.47×10^-14
3	细胞因子受体结合	14	3.98×10^-7
4	蛋白质同源二聚化活性	12	1.35×10^-9
5	蛋白酶结合泛素样	11	1.10×10^-11
6	RNA聚合酶II转录因子结合	10	1.38×10^-10
7	蛋白连接酶结合	9	1.32×10^-8
8	激酶调节活性	9	2.69×10^-5
9	蛋白激酶活性	9	3.80×10^-5
10	内肽酶活性	8	5.25×10^-9

序号	生物学过程	基因数	P值
1	凋亡信号通路	30	5.62×10^-30
2	损伤反应	30	1.17×10^-27
3	血管发育反应过程	30	1.00×10^-26
4	细胞粘附的调节	27	4.57×10^-23
5	对有毒物质的反应	26	7.08×10^-26
6	对无机物的反应	26	4.27×10^-25
7	生长调节	24	1.58×10^-20
8	跨膜受体蛋白酪氨酸激酶信号通路	24	3.47×10^-19
9	对损伤活性氧代谢过程	23	1.74×10^-27
10	对脂多糖的反应	23	5.13×10^-26

序号	细胞组分	基因数	P值
1	膜筏	15	1.70×10^-39
2	细胞外间质	10	2.63×10^-34
3	核被膜	9	9.77×10^-31
4	膜侧	9	1.86×10^-25
5	质膜蛋白复合物	9	2.51×10^-23
6	细胞质核周区	9	3.55×10^-19
7	胞体	7	3.98×10^-19
8	RNA聚合酶II转录调节复合物	6	9.55×10^-19
9	突触后膜	6	1.70×10^-18
10	血小板α颗粒腔	5	3.63×10^-11

Analysis of the mechanism of Dipsaci Radix-Taxilli Herba underlying the improvement of polycystic ovary syndrome via network pharmacology and molecular docking

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 10

References 37

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LIU Kechun, WANG Yongcheng, ZANG Xiaohan, XIA Qing, ZHANG Yun, ZHANG Shanshan, SUN Chen. Advancements in network pharmacology and zebrafish modeling for studying traditional Chinese medicine’s effective substances and mechanisms of action [J]. Shandong Science, 2024, 37(2): 29-35.
[2]	FU Zhaoju, CHENG Guo, LIN Dengmei, LI Jun, ZHANG Nannan. Experimental study and network pharmacological analysis of the anti-inflammatory action mechanism of Mahonia bealei (Fort.) Carr. [J]. Shandong Science, 2024, 37(1): 24-31.
[3]	CHEN Chun, QI Daqing, PAN Jingwen. Clinical significance of stromal cell score in gastric cancer and intervention with Weifuchun capsules [J]. Shandong Science, 2023, 36(6): 38-47.
[4]	MU Nana, LIAO Binbin, LI Zhen, LI Jipin, LI Yihua, WANG Ying, CHEN Xubing. Investigating the mechanism of action of Elephantopus scaber L. in the treatment of ulcerative colitis based on network pharmacology and molecular docking [J]. Shandong Science, 2023, 36(6): 48-55.
[5]	WANG Yifan, ZHANG Zhe, TIAN Caijun. Mechanism of Sanhuang Xiexin decoction in treatment of Alzheimer's disease based on network pharmacology and molecular docking method [J]. Shandong Science, 2023, 36(5): 19-26.
[6]	FU Mengya, AO Huihao, BU Chao, PENG Tangyi, WU Deling, HAN Yanquan, HONG Yan. Forecast analysis of the quality markers of Zingiberis Rhizoma based on fingerprints and network pharmacology [J]. Shandong Science, 2023, 36(4): 35-41.
[7]	YIN Zhipeng, GAO Yunyun, LIU Wenwen, GUO Pengbo, ZHAO Yinghui. Exploring the mechanism of Xiangsha Liujunzi Decoction in treating Helicobacter pylori-associated gastritis based on network pharmacology and molecular docking technology [J]. Shandong Science, 2023, 36(4): 52-60.
[8]	SUN Tiefeng, DONG Limin, JIAO Ziqi, WANG Ping. Exploration of the dosing pattern and anti-respiratory syncytial virus mechanism of traditional Chinese medicine based on data mining and network pharmacology [J]. Shandong Science, 2023, 36(3): 1-9.
[9]	ZHU Jie, WANG Zheng, LIANG Yanni. The mechanism of Xiaoqinglong Decoction in treatment of COVID-19 based on network pharmacology [J]. Shandong Science, 2023, 36(3): 10-17.
[10]	DONG Pengjun, CAI Bin. Action mechanism of the herb pair Aurantii Fructus Immaturus-Magnoliae Officinalis Cortex in the treatment of slow transit constipation based on network pharmacology and metabolomics [J]. Shandong Science, 2023, 36(3): 18-26.
[11]	ZHAO Xin, HUANG Biyun, WU Dan, ZHANG Mei. The mechanism of Guishaozhenxian Tablet in the treatment of temporal lobe epilepsy based on network pharmacology and molecular docking [J]. Shandong Science, 2023, 36(3): 27-37.
[12]	WANG Yifan, ZHANG Yanyan, TIAN Caijun. Network pharmacology to explore the mechanism of Wangbi formula in the treatment of rheumatoid arthritis [J]. Shandong Science, 2023, 36(3): 38-45.
[13]	LIU Wenwen, GAO Yunyun, YIN Zhipeng, LÜ Gang, WANG Yu, ZHAO Yinghui. Network pharmacology and molecular docking analysis of the mechanism of Huanglian Wendan Decoction in the treatment of Helicobacter pylori associated gastritis [J]. Shandong Science, 2023, 36(2): 23-32.
[14]	LIU Wenwen, LI Changgeng, KONG Na, LIU Shuang, DONG Hongjing. Study on the mechanism of Shiweiyipi Granules based on network pharmacology and molecular docking [J]. Shandong Science, 2023, 36(2): 33-40.
[15]	SHEN Fengxia, FAN Jianwei, LI Qian, MA Yun, FENG Qun, GUAN Yongxia. Analysis of the mechanism of Yinzhihuang Granules in liver fibrosis treatment based on network pharmacology and molecular docking [J]. Shandong Science, 2023, 36(1): 23-33.